Calcineurin Inhibitors Market Report 2025

The calcineurin inhibitors market size has grown strongly in recent years. It will grow from $8.84 billion in 2024 to $9.49 billion in 2025 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to faster regulatory approvals for immunosuppressants, favorable reimbursement policies for transplant medications, increasing government support for organ transplantation, expansion of healthcare infrastructure, growth of specialty pharmacies distributing immunosuppressants.

The calcineurin inhibitors market size is expected to see strong growth in the next few years. It will grow to $12.8 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to calcineurin inhibitors market, rising prevalence of autoimmune diseases, growing cases of chronic kidney diseases leading to transplants, higher incidence of atopic dermatitis and psoriasis, expanding patient pool for immunosuppressive therapies. Major trends in the forecast period include advancements in drug formulation for better efficacy, development of extended-release formulations, research on combination therapies with calcineurin inhibitors, innovations in drug delivery methods, improved understanding of t-cell signaling pathways.

The forecast of 7.8% growth over the next five years reflects a modest reduction of 0.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. transplant programs by inflating prices of calcineurin inhibitors manufactured in Ireland and Japan, resulting in delayed post-operative immunosuppression and higher organ transplantation costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growing number of organ transplants is expected to drive the expansion of the calcineurin inhibitors market. Organ transplants involve the surgical replacement of a damaged or failing organ with a healthy one from a donor. The incidence of organ transplants is rising due to the increasing prevalence of chronic diseases such as diabetes and hypertension, which often lead to organ failure and heighten the demand for transplants. Calcineurin inhibitors play a crucial role in organ transplantation by inhibiting T-cell activation, preventing the immune system from recognizing the transplanted organ as foreign, and reducing the risk of rejection. This enhances the long-term survival of the graft. For example, in January 2025, the Organ Procurement and Transplantation Network (OPTN), a U.S.-based transplant information database, reported that organ transplants exceeded 48,000 in 2024, reflecting a 3.3% increase compared to 2023. Therefore, the rise in organ transplant procedures is fueling the growth of the calcineurin inhibitors market.

Key players in the calcineurin inhibitors market are concentrating on the development of immunosuppressive therapies, including treatments for autoimmune diseases, aimed at controlling excessive immune responses, reducing inflammation, and preventing tissue damage. These therapies, which include corticosteroids, immunosuppressants, biologics, and disease-modifying antirheumatic drugs (DMARDs), help regulate the immune system by suppressing overactive immune responses. For example, in April 2024, Biocon Limited, an India-based biopharmaceutical company, received approval from the South African Health Products Regulatory Authority (SAHPRA) for Tacrolimus, a calcineurin inhibitor and immunosuppressant used to prevent organ rejection in transplant patients. Tacrolimus has been effective in renal transplants for over two decades. It works by binding to the immunophilin FKBP-12, forming a complex that inhibits calcineurin activity, reducing the production of interleukin-2 (IL-2) and T-cell proliferation, which are crucial in the immune response against transplanted organs.

In July 2023, Harrow Inc., a U.S.-based eyecare pharmaceutical company, acquired Santen’s branded ophthalmic portfolio for an undisclosed amount. The acquisition provided Harrow with commercial rights to six branded products from Santen, including VERKAZIA (cyclosporine ophthalmic emulsion) 0.1%, a calcineurin inhibitor used to treat vernal keratoconjunctivitis (VKC) in both children and adults, with orphan-drug exclusivity. This acquisition strengthens Harrow’s position in the U.S. ophthalmic pharmaceutical market and supports its strategy to become a leading industry player while significantly expanding its branded product offerings. Santen Pharmaceutical Co. Ltd., based in Japan, is a key manufacturer of calcineurin inhibitors.

Major players in the calcineurin inhibitors market are Pfizer Inc., Roche Holding AG, Bristol-Myers Squibb Company, Novartis AG, Viatris Inc., Astellas Pharma Inc., Bausch Health Companies Inc., Huadong Medicine Co. Ltd., Sun Pharmaceutical Industries Ltd., Apotex Inc., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Lupin Pharmaceutical Inc., Zydus Cadila, Biocon Limited, Glenmark Pharmaceuticals Ltd., Accord Healthcare Ltd., Strides Pharma Science Limited, Harrow Inc., and Panacea Biotec Ltd.

North America was the largest region in the calcineurin inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in calcineurin inhibitors report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the calcineurin inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The calcineurin inhibitors market consists of sales of topical formulations and diagnostic and monitoring tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment - many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The calcineurin inhibitors market research report is one of a series of new reports that provides calcineurin inhibitors market statistics, including calcineurin inhibitors industry global market size, regional shares, competitors with a calcineurin inhibitors market share, detailed calcineurin inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the calcineurin inhibitors industry. This calcineurin inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Calcineurin inhibitors (CNIs) are a class of immunosuppressant drugs that function by inhibiting calcineurin, a key enzyme involved in T-cell activation, thereby reducing immune responses. These drugs are primarily used to prevent organ transplant rejection and to treat autoimmune diseases such as psoriasis and atopic dermatitis. The most commonly used CNIs are cyclosporine and tacrolimus, both of which block the production of interleukin-2 (IL-2), a vital cytokine for T-cell proliferation.

The main forms of calcineurin inhibitors are branded and generic versions. Branded calcineurin inhibitors are patented immunosuppressant drugs marketed under specific trade names by pharmaceutical companies. These are available in various dosages, including tablets, capsules, ointments, injections, and other forms. They are used for organ transplantation, autoimmune diseases, and other conditions. The primary end users of these drugs include hospitals, homecare settings, and pharmacies.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.